- Home
- WNW vs GTBP Comparison
WNW vs GTBP Comparison
Compare WNW & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- GTBP
- Stock Information
- Founded
- WNW 2015
- GTBP 1965
- Country
- WNW China
- GTBP United States
- Employees
- WNW N/A
- GTBP N/A
- Industry
- WNW Catalog/Specialty Distribution
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- GTBP Health Care
- Exchange
- WNW Nasdaq
- GTBP Nasdaq
- Market Cap
- WNW 5.4M
- GTBP 5.5M
- IPO Year
- WNW 2020
- GTBP N/A
- Fundamental
- Price
- WNW N/A
- GTBP $1.08
- Analyst Decision
- WNW
- GTBP Strong Buy
- Analyst Count
- WNW 0
- GTBP 1
- Target Price
- WNW N/A
- GTBP $11.00
- AVG Volume (30 Days)
- WNW 47.6K
- GTBP 4.0M
- Earning Date
- WNW 11-14-2025
- GTBP 11-13-2025
- Dividend Yield
- WNW N/A
- GTBP N/A
- EPS Growth
- WNW N/A
- GTBP N/A
- EPS
- WNW 9.06
- GTBP N/A
- Revenue
- WNW $158,485.00
- GTBP N/A
- Revenue This Year
- WNW N/A
- GTBP N/A
- Revenue Next Year
- WNW N/A
- GTBP N/A
- P/E Ratio
- WNW $0.23
- GTBP N/A
- Revenue Growth
- WNW N/A
- GTBP N/A
- 52 Week Low
- WNW $0.95
- GTBP $0.55
- 52 Week High
- WNW $70.00
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- WNW N/A
- GTBP 40.05
- Support Level
- WNW N/A
- GTBP $0.62
- Resistance Level
- WNW N/A
- GTBP $0.68
- Average True Range (ATR)
- WNW 0.00
- GTBP 0.09
- MACD
- WNW 0.00
- GTBP 0.03
- Stochastic Oscillator
- WNW 0.00
- GTBP 60.13
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.